Protective Effect of Paraoxonase 1 Gene Variant Gln192Arg in Age-Related Macular Degeneration

American Journal of Ophthalmology

Volumn 149, Issue 3, 2010, Pages 513-522

  Pauer, Gayle J T ^a,c   Sturgill, Gwen M ^b,c   Peachey, Neal S ^a,b,c   Hagstrom, Stephanie A ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1;

AGED; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SINGLE STRAND CONFORMATION POLYMORPHISM;

AGED; AGED, 80 AND OVER; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SEQUENCE ANALYSIS, DNA; WET MACULAR DEGENERATION;

EID: 76749102415     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.09.024     Document Type: Article

References (40)

1. Stone E.M. Macular degeneration. Annu Rev Med 58 (2007) 477-490
2. Evans J.R. Risk factors for age-related macular degeneration. Prog Retin Eye Res 20 (2001) 227-253
3. Hollman F.W., Mulder T.J., and Kallan J.E. Methodology and assumptions for the population projections of the United States: 1999-2100 (2003), Popul Proj Branch Popul Div, US Census Bureau, Washington, D.C 1-34
4. Friedman D.S., O'Colmain B.J., Muñoz B., et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122 (2004) 564-572
5. Swaroop A., Branham K.E., Chen W., and Abecasis G. Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits. Hum Mol Genet 16 (2007) 174-182
6. Haddad S., Chen C.A., Santangelo S.L., and Seddon J.M. The genetics of age-related macular degeneration: a review of progress to date. Surv Ophthalmol 51 (2006) 316-363
7. Klein R.J., Zeiss C., Chew E.Y., et al. Complement factor H polymorphism in age-related macular degeneration. Science 308 (2005) 385-389
8. Haines J.L., Hauser M.A., Schmidt S., et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308 (2005) 419-421
9. Edwards A.O., Ritter R., Abel K.J., Manning A., Panhuysen C., and Farrer L.A. Complement factor H polymorphism and age-related macular degeneration. Science 308 (2005) 421-424
10. Hageman G.S., Anderson D.H., Johnson L.V., et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 102 (2005) 7053-7054
11. Gold B., Merriam J.E., Zernant J., et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 38 (2006) 458-462
12. Yates J.R., Sepp T., Matharu B.K., et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 357 (2007) 553-561
13. Seddon J.M., Willett W.C., Speizer F.E., and Hankinson S.E. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 276 (1996) 1141-1146
14. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119 (2001) 1417-1436
15. Marchegiani F., Marra M., Olivieri F., et al. Paraoxonase 1: genetics and activities during aging. Rejuvenation Res 11 (2008) 113-127
16. Draganov D.I., and La Du B.N. Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 78-88
17. Furlong C.E., Li W.-F., Shih D.M., Lusis A.J., Richter R.J., and Costa L.G. Genetic factors in susceptibility: Serum PON1 variation between individuals and species. Hum Ecol Risk Assess 8 (2002) 31-43
18. Primo-Parmo S.L., Sorenson R.C., Teiber J., and La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33 (1996) 498-507
19. Adkins S., Gan K.N., Mody M., and La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52 (1993) 598-608
20. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., and Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3 (1993) 73-76
21. Garin M.C., James R.W., Dussoix P., et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99 (1997) 62-66
22. Iselius L., Evans D.A., and Playfer J.R. Genetics of plasma paroxonase activity. J Med Genet 19 (1982) 424-426
23. Leviev I., and James R.W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20 (2000) 516-521
24. Brophy V.H., Jampsa R.L., Clendenning J.B., McKinstry L.A., Jarvik G.P., and Furlong C.E. Effects of 5_ regulatory-region polymorphisms on paraoxonase gene (PON1) expression. Am J Hum Genet 68 (2001) 1428-1436
25. Deakin S., Leviev I., Brulhart-Meynet M.C., and James R.W. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position-107, implicating the Sp1 transcription factor. Biochem J 372 (2003) 643-649
26. Leviev I., Deakin S., and James R.W. Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J Lipid Res 42 (2001) 528-535
27. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., and Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14 (1996) 334-336
28. Ikeda T., Obayashi H., Hasegawa G., et al. Paraoxonase gene polymorphisms and plasma oxidaized low-density lipoprotein level as possible risk factors for exudative age-related macular degeneration. Am J Ophthalmol 132 (2001) 191-195
29. Baird P.N., Chu D., Guida E., Vu H.T., and Guymer R. Association of the M55L and Q192R paraoxonase gene polymorphisms with age-related macular degeneration. Am J Ophthalmol 138 (2004) 665-666
30. Esfandiary H., Chakravarthy U., Patterson C., Young I., and Hughes A.E. Association study of detoxification genes in age related macular degeneration. Br J Ophthalmol 89 (2005) 470-474
31. Xi Q., Pauer G.J., Traboulsi E.I., and Hagstrom S.A. Mutation screen of the TUB gene in patients with retinitis pigmentosa and Leber congenital amaurosis. Exp Eye Res 83 (2006) 569-573
32. Ramensky V., Bork P., and Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30 (2002) 3894-3900
33. Ferrer-Costa C., Gelpí J.L., Zamakola L., Parraga I., de la Cruz X., and Orozco M. PMUT: a web-based tool for the annotation of pathological mutations on proteins. Bioinformatics 21 (2005) 3176-3178
34. Beatty S., Koh H., Phil M., Henson D., and Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45 (2000) 115-134
35. Winkler B.S., Boulton M.E., Gottsch J.D., and Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis 5 (1999) 32
36. Baskol G., Karakucuk S., Oner A.O., et al. Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration. Ophthalmologica 220 (2006) 12-16
37. Ates O., Azizi S., Alp H.H., et al. Decreased serum paraoxonase 1 activity and increased serum homocysteine and malondialdehyde levels in age-related macular degeneration. Tohoku J Exp Med 217 (2009) 17-22
38. Wheeler J.G., Keavney B.D., Watkins H., Collins R., and Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363 (2004) 689-695
39. Bhattacharyya T., Nicholls S.J., Topol E.J., et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299 (2008) 1265-1276
40. Richter R.J., and Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9 (1999) 745-753